A milestone toward commercial deployment of VisionAI.
Ainnova Tech began diabetic retinopathy screenings through its joint venture with Avant Technologies, marking an important milestone on the path from development to real-world commercial deployment of VisionAI.
By bringing fast, non-invasive retinal screening to the point of care, Ainnova helps providers detect diabetic retinopathy earlier — when timely intervention can prevent vision loss.
The screenings were carried out through Ainnova's joint venture with Avant Technologies. By pairing Ainnova's VisionAI software with retinal imaging, the venture aimed to make diabetic retinopathy screening faster and more accessible at the point of care.
Diabetic retinopathy is a leading cause of preventable blindness, which makes early, accessible screening critical.
Ainnova Tech is a healthcare technology company focused on revolutionizing early disease detection using artificial intelligence. Its platform, VisionAI, analyzes retinal images to detect early markers of diseases such as diabetic retinopathy — with a growing portfolio spanning cardiovascular, metabolic, liver and kidney risk. Ainnova is dedicated to making healthcare more proactive, accessible and efficient.
Source: Press release on Nasdaq ↗
Contact: Ainnova Tech — info@ainnovatech.com